Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1.53 USD | +0.66% | +11.68% | +73.86% |
Kurzporträt
Mitarbeiterzahl: 12
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01.12.08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01.12.08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01.01.17 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 04.12. |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 25.10.22 |
Delly Behen
ADM | Chief Administrative Officer | - | 01.01.14 |
Eric van Zanten
IRC | Investor Relations Contact | - | 07.12.22 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01.12.08 |
Director/Board Member | 66 | 01.03.14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01.02.12 |
Shu-Chih Chen
FOU | Founder | 62 | 01.12.08 |
Stephen Galli
BRD | Director/Board Member | 77 | 01.07.11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 08.11. |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 126 624 110 | 125 230 652 ( 98,90 %) | 1 320 046 ( 1,042 %) | 98,90 % |
Aktie B | 0 | 582 | 0 | 0 |
Unternehmenskontakt
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSektor
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+73.86% | 192 Mio. | |
+1.51% | 42.75 Mrd. | |
+49.22% | 41.61 Mrd. | |
+8.57% | 41.34 Mrd. | |
-12.36% | 26.59 Mrd. | |
+8.92% | 25.49 Mrd. | |
-25.13% | 18.12 Mrd. | |
+29.17% | 12.24 Mrd. | |
-3.12% | 11.76 Mrd. | |
+6.35% | 11 Mrd. |
- Börse
- Aktien
- A2JJ99 Aktie
- Unternehmen Atossa Therapeutics, Inc.